Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
January 2020
-
Key ReleaseSandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicinesSuccessful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicinesAcquired portfolio complements…
-
Media ReleaseNovartis Cosentyx® builds on its axSpA leadership with US label update for dosing flexibility in ankylosing spondylitisNew Cosentyx® (secukinumab) US label to include 300 mg up-titration option is based on Phase III MEASURE 3 study results in ankylosing spondylitis (AS)1 Label update provides clinicians with…
-
Key ReleaseNovartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019Full year net sales for continuing operations1 up 9% (cc2, +6% USD): Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and…
-
Key ReleaseNovartis erzielt 2019 ein starkes Umsatzwachstum, Margen-steigerungen und bahnbrechende Innovationen mit der Markt¬einführung fünf neuer WirkstoffeDer Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt 2019 um 9% (kWk2, +6% USD): Die Geschäftseinheit Pharmaceuticals wächst um 12% (kWk), getragen von Cosentyx (USD 3,6 …
-
Key ReleaseNovartis a réalisé en 2019 une forte croissance de son chiffre d’affaires, une augmentation de sa marge et une percée dans l’innovation en lançant cinq nouvelles entités moléculairesHausse du chiffre d’affaires net des activités poursuivies1 de 9% sur l’exercice entier (tcc2, +6% USD): Pharmaceuticals: cette unité opérationnelle progresse de 12% (tcc), sous l’impulsion de…
-
Media ReleaseNovartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active diseaseMayzent® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe1 Mayzent…
-
Media ReleaseNovartis ligelizumab (QGE031) more effective than Xolair® at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticariaData show ligelizumab binds to immunoglobulin E (IgE), a key driver of chronic spontaneous urticaria (CSU), with significantly higher affinity than current standard of care Xolair (omalizumab)1 …
-
Media ReleaseNovartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiranOver 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL…
-
Key ReleaseNovartis completes tender offer for all outstanding shares of The Medicines CompanyBasel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger…
December 2019
-
Media ReleaseAveXis Community Statement on Global Managed Access Program for AVXS-101Dear SMA Community, Since its U.S. approval, AveXis has had increasing demand from families outside of the U.S. for access to AVXS-101. While we are pursuing registration in close to three dozen…
-
Key ReleaseNovartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthmaPooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipiprant was well tolerated with adverse events balanced across…
Pagination
- ‹ Previous page
- 1
- …
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- …
- 100
- › Next page